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Abstract
Cryptococcal meningitis remains a substantial health burden with high morbidity, particularly in
developing countries. Antifungal treatment regimens are guided by host factors, severity of illness
(including presence of complications), and causative cryptococcal species. Recent clinical studies
indicate the need for rapidly fungicidal induction therapy regimens using amphotericin B in combination
with flucytosine for optimal outcomes. Maintenance therapy with fluconazole is necessary until
recovery of immune function. Cryptococcus gattii meningitis requires prolonged induction/eradication
therapy. Prompt control of raised intracranial pressure or hydrocephalus is essential. Clinicians should
be vigilant for immune restoration-like features. Adjuvant surgery, corticosteroids, and/or recombinant
interferon-gamma may be required for large cryptococcomas, cerebral edema, or refractory infection.
Introduction and context
Human cryptococcosis is most commonly caused by
Cryptococcus neoformans and Cryptococcus gattii,w i t h
C. neoformans var. grubii in patients with AIDS accounting
for the majority of infections worldwide. Clinical features
and complications of infection caused by the two species
are influenced by differences in epidemiology and host
association (reviewed in [1,2]). For example, there is a
greater propensity for C. gattii than for C. neoformans to
cause disease in immunocompetent hosts and to be
associated with large mass lesions or cryptococcomas [3].
These differences may influence intervention strategies.
Cryptococcal meningoencephalitis (CM), the most
severe form of cryptococcosis, typically affects the high-
risk population groups of HIV/AIDS and organ trans-
plantation patients but also affects individuals without
apparent immunocompromise [3-5]. Key management
issues include the employment of rapidly fungicidal
regimens in the induction phase of antifungal treatment
followed by adequate suppressive therapy, as well as
early recognition and treatment of complications of CM
such as raised intracranial pressure (ICP) and the
immune response inflammatory syndrome (IRIS)
[1,6,7], optimal management of large cerebral crypto-
coccomas, and treatment strategies in resource-limited
settings [8,9].
Recent advances
Recent advances in clinical research include those
directed at better defining prognostic determinants of
outcome, especially in HIV-infected individuals, and the
application of these findings to treatment algorithms
[10,11]. The overall management of cryptococcosis is
detailed in the new clinical practice guidelines of the
Infectious Diseases Society of America [1]. These include
specific recommendations for unique risk populations
such as children, pregnant women, those with C. gattii
infection, and those in in resource-limited environments.
Meningoencephalitis in HIV/AIDS
Randomized controlled trials (RCTs) of drug therapy
of CM due to C. neoformans in HIV/AIDS formalized the
concept of induction, consolidation (eradication), and
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severely immunosuppressed (Table 1) [1]. Rapidly fungi-
cidal induction therapy regimens are essential for favor-
ableoutcomes[12].Inparticular,combinedamphotericin
B (AMB)-flucytosine regimens result in faster sterilization
of cerebrospinal fluid (CSF) and superior clinical or
mycological outcomes at 2 weeks and at 3 months in
comparison with AMB alone, AMB plus fluconazole, or
fluconazole alone [10,11,13]. This difference has been
most evident in patients with high initial CSF fungal
burdens or abnormal neurological features (or both) at
presentation. Conversely, receipt of initial flucytosine for
fewer than 14 days has been independently linked with
treatment failure at 3 months of therapy [11]. None-
theless, the only large randomized phase III study of AMB
with and without flucytosine (in patients with AIDS)
failed to demonstrate a clinical benefit of combination
therapy [14]. Conventional AMB (c-AMB) at a daily dose
of 1 mg/kg (in combination with flucytosine) is more
rapidly fungicidal than a dose of 0.7 mg/kg [10]; duration
of therapy depends on clinical response and treatment
regimen (Table 1). Although there are fewer reports of
lipid AMB formulations in combination with flucytosine
for treating CM, clinical experience strongly suggests
that such combination therapy is effective (reviewed in
[1]) and there is consensus that either liposomal AMB
(3-4 mg/kg daily) or AMB lipid complex (5 mg/kg daily)
could be substituted for c-AMB in patients with or
predisposed to renal dysfunction [1].
Induction regimens with fluconazole plus flucytosine
or with fluconazole monotherapy have been used,
especially in resource-limited areas (see below), but are
less effective and are indicated only when first-line drugs
cannot be used [1]. If fluconazole is to be used as a single
agent, a daily dose of 1200-2000 mg is recommended
[15,16]. Following induction/consolidation therapy,
fluconazole should be continued until immune recon-
stitution with HAART (highly active antiretroviral ther-
apy) [1]. Voriconazole and posaconazole can be used as
salvage therapy for all patient groups (see below) [1].
When C. gattii affects patients with AIDS, clinical features
appear to be similar to those of C. neoformans var. grubii
[17], suggesting that management should also be similar.
There are retrospective data showing that the course
and outcomes of CM (without cerebral mass lesions or
hydrocephalus) are independent of causative cryptococ-
cal species [1].
Meningoencephalitis in organ transplantation
Given the likelihood of nephrotoxicity with concurrent
use of c-AMB and calcineurin inhibitors and given that
approximately 25% of all organ recipients with crypto-
coccosis have renal dysfunction, lipid AMB formulations
are often employed as induction therapy in combination
with flucytosine (Table 1). The median time to CSF
sterilization is approximately 10 days, and 2-6 weeks of
induction therapy (depending on whether flucytosine is
given)arerecommended [1].Recently,itwas documented
for the first time in solid-organ transplant recipients that
the use of lipid AMB formulations to treat CM indepen-
dently predicted better outcomes (compared with c-AMB)
[5].However,clinicaloutcomesweremeasuredat90days,
Table 1. Antifungal treatment for cryptococcal meningoencephalitis and disseminated disease
Clinical setting Induction therapy Duration Consolidation/maintenance therapy Duration
HIV-infected
individuals
c-AMB (0.7-1 mg/kg daily) plus flucytosine
(100 mg/kg daily)
2 weeks Consolidation: fluconazole (400 mg daily)
Maintenance: fluconazole (200 mg daily)
8 weeks
or
L-AMB (3-4 mg/kg daily) or ABLC (5 mg/kg daily)
(if there are renal function concerns) plus
flucytosine (100 mg/kg daily)
2 weeks Itraconazole (400 mg daily)
a





c-AMB or L-AMB or ABLC (doses as above) for
flucytosine-intolerant patients




L-AMB (3-4 mg/kg daily) or ABLC (5 mg/kg daily)
plus flucytosine (100 mg/kg daily)
2 weeks Consolidation: fluconazole (400-800 mg daily)
Maintenance: fluconazole (200-400 mg daily)
8 weeks
or
L-AMB (6 mg/kg daily) or ABLC (5 mg/kg daily) or
c-AMB (0.7 mg/kg daily)
4-6 weeks 6-12 months
Non-HIV, non-
transplant patients
c-AMB (0.7-1 mg/kg daily) plus flucytosine
(100 mg/kg daily)
≥4 weeks Consolidation: fluconazole (400-800 mg daily)
Maintenance: fluconazole (200 mg daily)
8 weeks
or
L-AMB (3-4 mg/kg daily) or ABLC (5 mg/kg daily)
plus flucytosine
c-AMB or L-AMB or ABLC (in above doses)
without flucytosine
≥6 weeks 6-12 months
ABLC, amphotericin B lipid complex; c-AMB, amphotericin B deoxycholate; L-AMB, liposomal amphotericin B.
aInferior to fluconazole.
bWith CD4 count at
least 100 cells per microliter and undetectable viral load for at least 3 months with a minimum of 1 year of antifungal therapy.
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evaluate efficacy of different antifungal therapies. There
are data to suggest that calcineurin inhibitors demonst-
rate synergistic effects in vitro with antifungal agents and
may be associated with better outcomes in solid-organ
transplant patients with cryptococcosis [18].
Since most relapses in patients not prescribed mainte-
nance therapy occur within 6 months [1,19], consolida-
tion/maintenance fluconazole therapy for 6-12 months
(relapse rate of 1.3%) is recommended. Azole-drug inter-
actions may be problematic. Reduction of immunosup-
pressive therapy should be gradual to minimize the risk of
allograft loss and development of IRIS [6,19].
Neurocryptococcosis in non-immunocompromized hosts
InuncomplicatedC.neoformansmeningitis,opinion(there
are no RCT data) favors induction with c-AMB or a lipid
formulation and flucytosine for 2 weeks (in the absence of
adverse prognostic factors such as abnormal neurological
findings or altered mental status) or 4-6 weeks provided
that 2-week CSF cultures are negative [1] (Table 1). One
recent retrospective study of 154 patients without HIV/
AIDS, of whom 103 had no immune compromise,
reported that initial therapy with non-AMB-containing
regimens was independently associated with increased
mortality [20]. Experts treating C. gattii meningitis also
favor 4-6 weeks of therapy on the basis of clinical
experience [1]. Although fluconazole (with or without
flucytosine) is not recommended for induction therapy,
it is the drug of choice (400 mg/day) for eradication
(8 weeks) and maintenance (6-12 months) therapy to
prevent relapse. Compared with C. neoformans,i n tr a c r a n i a l
C. gattii infection is associated with a greater number of
neurological sequelae and delayed responses to therapy,
primarily because of a higher proportion of cerebral mass
lesions (cryptococcomas) and late presentations [1,3].
Other management
Another important determinant of outcome is control of
raised ICP by repeated lumbar puncture and/or by early
shunting; symptomatic hydrocephalus requires antifun-
gal therapy plus early shunting [1,2]. In the absence of
cryptococcomas, the antifungal regimen should be the
same as for meningitis. Large cryptococcomas should be
treated with combination antifungal therapy and early
surgical removal as response to antifungal drugs is poor.
Multiple lesions require prolonged induction/eradica-
tion therapy [3]. Corticosteroids may be required if there
is substantial surrounding edema, especially in the
presence of neurological deficits [1].
The duration of induction/eradication antifungal ther-
apy depends on clinical and mycological responses.
Re-imaging in cases of apparent relapse may reveal new/
enlarging lesions, with increased perilesional edema
despite antifungal therapy. This appears to result from
IRIS, as has been reported for C. gattii infection and
organ transplant/HIV-positive patients following recov-
ery of immune function. Apart from enhancing central
nervous system (CNS) lesions, C. neoformans-associated
IRIS may manifest in the CNS as increased ICP and
inflammatory lesions within the spinal cord and
typically also presents as lymphadenitis, skin, or soft
tissue lesions [6,7]. Short-course corticosteroids have
been used successfully alongside antifungal therapy
[6,21,22]. Adjunctive recombinant interferon-gamma
therapy has been tried in C. gattii infection unresponsive
to repeated/prolonged courses of antifungal drugs [1,2].
Its contribution to outcomes is uncertain.
Resource-limited settings
Treatment of CM in areas where only c-AMB and
fluconazole are widely available has been recently
assessed. Donated fluconazole (200-400 mg daily) for
8-10 weeks is often the only treatment option, especially
in Africa [23], but there are no data to recommend
fluconazole as first-line therapy [9]. The only study
comparing the efficacy of fluconazole and c-AMB is an
older American study that showed non-inferiority bet-
ween the two agents. This study, however, had excluded
severely ill patients, included patients who were under-
going re-treatment of their infection, and had employed
a low dose of c-AMB (0.3 mg/kg daily) [24].
In developed countries, flucytosine-AMB combinations
are the preferred induction treatment regimens in HIV/
AIDS. Where flucytosine-AMB combinations are not
available, relevant authorities should consider procuring
flucytosine for CM treatment programs. Antifungal
prophylaxis programs have shown mixed results [22].
Implications for clinical practice
Major determinants of outcome of CM include neuro-
logical status, ICP, presence of cerebral mass lesions, and
cryptococcal load at presentation. CSF pressure should
always be assessed and raised ICP relieved promptly.
Rapidly fungicidal induction treatment regimens are the
key to optimal outcomes in all patients. Flucytosine, in
combination with AMB, remains the induction regimen
ofchoice;theimportance offlucytosinehasbeendemon-
strated in a number of studies and RCTs. In organ
transplant patients, use of lipid AMB, over c-AMB, has
been linked with superior outcomes. Longer courses of
induction/eradication therapy are required in C. gattii
infection. Shunting to relieve symptomatic hydrocepha-
lus, and resection of large cryptococcomas, usually due
to C. gattii, may be necessary. In patients with substantial
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red to control the pathogenic process.
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